Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Summary

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Pleural Biphasic Mesothelioma
• Pleural Sarcomatoid Mesothelioma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Alliance for Clinical Trials in Oncology

Last updated on ClinicalTrials.gov

August 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites